• Lee M Gelpi Acevedo, Alexandra Lizette Salinas, Juan Sebastian Polanco, Hamasah Nizami, Denise Marsh, Meet Patel, Kinna Parikh, Rahul Jain, and Rohit Jain.
• From the Department of Medicine, Universidad Autónoma de Guadalajara School of Medicine, Guadalajara, Jalisco, Mexico, Department of Medicine, American University of Integrative Sciences, Tucker, Georgia, Department of Medicine, University of Pittsburgh Medical Center Western Maryland Health System, Cumberland, Maryland, Tianjin Medical University, Tianjin, P.R. China, GMERS Medical College, Gandhinagar, Gujarat, India, Department of Cardiology, School of Medicine University of Missouri, Columbia, Missouri, and Department of Internal Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.
• South. Med. J. 2022 Dec 1; 115 (12): 926929926-929.

AbstractHypertrophic cardiomyopathy (HCM) is a genetic autosomal dominant disorder of the heart muscle that is characterized by left ventricular hypertrophy and sudden cardiac death. It is the most common inherited cardiac disease. HCM is defined by sarcomeric mutations that result in fibrosis of the heart, affecting contraction. In most cases, clinical presentations can range from asymptomatic to systolic and diastolic ventricular dysfunction, arrhythmias, and sudden cardiac death. Some histopathologic features typical of the disease are changes in myocyte disarray and myocardial fibrosis. Mutations in the β-myosin heavy chain and myosin-binding protein C have been identified as the cause of the disease. The goals of pharmacological therapy as well as nonpharmacological therapy are to alleviate the symptoms and to prevent sudden cardiac death. Anatomical defects are treated primarily by surgical intervention, whereas other issues such as hypercontractility are treated with pharmacotherapy. In this article, we review the pathophysiology and treatment options for HCM.

22 keywords...

hide…